Spero Therapeutics (NASDAQ:SPRO – Get Free Report) and Kiora Pharmaceuticals (NASDAQ:KPRX – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings.
Profitability
This table compares Spero Therapeutics and Kiora Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Spero Therapeutics | N/A | N/A | N/A |
| Kiora Pharmaceuticals | N/A | N/A | N/A |
Insider & Institutional Ownership
25.6% of Spero Therapeutics shares are held by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 2.9% of Spero Therapeutics shares are held by insiders. Comparatively, 0.5% of Kiora Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Spero Therapeutics and Kiora Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Spero Therapeutics | 1 | 2 | 2 | 0 | 2.20 |
| Kiora Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
Spero Therapeutics currently has a consensus price target of $6.00, suggesting a potential upside of 426.32%. Given Spero Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Spero Therapeutics is more favorable than Kiora Pharmaceuticals.
Valuation & Earnings
This table compares Spero Therapeutics and Kiora Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Spero Therapeutics | N/A | N/A | N/A | $0.11 | 10.36 |
| Kiora Pharmaceuticals | N/A | N/A | N/A | ($2.51) | -0.92 |
Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Spero Therapeutics beats Kiora Pharmaceuticals on 6 of the 7 factors compared between the two stocks.
About Spero Therapeutics
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
About Kiora Pharmaceuticals
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
